Study · Randomized controlled trial · n = 106 · 2025

5 results

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M

Journal of the American College of Cardiology18 Nov 2024Cited by 124 (Europe PMC)

PMID39566869DOI10.1016/j.jacc.2024.11.001PepBankPUB-39566869

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related HFpEF, tirzepatide reduced left ventricular mass by 11 g more than placebo at 52 weeks.
In plain wordsIn adults with obesity-related heart failure, tirzepatide reduced the mass of the heart's main pumping chamber more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseLeft ventricular mass change
Study
n = 106
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg weekly, increasing to a maximum of 15 mg weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
LV mass change
−11 g
tirzepatide corrected for placebo
Source sentences
Summary
LV mass decreased by 11 g (95% CI: -19 to -4 g) in the treated group (n = 50) when corrected for placebo (n = 56) (P = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging.
Summary · context
A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks.
Report a problemFND-3956686901
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related HFpEF, tirzepatide reduced paracardiac adipose tissue by 45 mL more than placebo.
In plain wordsIn adults with obesity-related heart failure, tirzepatide reduced fat around the heart more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseParacardiac adipose tissue change
Study
n = 106
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg weekly, increasing to a maximum of 15 mg weekly · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Paracardiac adipose tissue change
−45 mL
tirzepatide corrected for placebo
Source sentences
Summary
Paracardiac adipose tissue decreased in the treated group by 45 mL (95% CI: -69 to -22 mL) when corrected for placebo (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging.
Summary · context
A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks.
Report a problemFND-3956686902
03HumanRandomized controlled trialMechanism
In tirzepatide-treated adults with obesity-related HFpEF, the change in LV mass correlated with the change in body weight.
In plain wordsIn adults with obesity-related heart failure on tirzepatide, the drop in heart muscle mass paralleled weight loss.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of LV mass change with body weight change
Study
n = 50
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg weekly, increasing to a maximum of 15 mg weekly · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
The change in LV mass in the treated group correlated with changes in body weight (P < 0.02)
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging.
Summary · context
A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks.
Report a problemFND-3956686903
04HumanRandomized controlled trialMechanism
In tirzepatide-treated adults with obesity-related HFpEF, the change in LV mass tended to correlate with changes in waist circumference and blood pressure, without reaching significance.
In plain wordsIn adults with obesity-related heart failure on tirzepatide, heart muscle mass change did not clearly track waist size or blood pressure changes.
Peptide
Tirzepatide
Outcome
No significant changeCorrelation of LV mass change with waist circumference and blood pressure changes
Study
n = 50
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg weekly, increasing to a maximum of 15 mg weekly · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
and tended to correlate with changes in waist circumference and blood pressure (P = 0.06 for both).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging.
Summary · context
A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks.
Report a problemFND-3956686904
05HumanRandomized controlled trialMechanism
In tirzepatide-treated adults with obesity-related HFpEF, the LV mass change correlated with changes in LV end-diastolic volume and left atrial end-diastolic and end-systolic volumes.
In plain wordsIn adults with obesity-related heart failure on tirzepatide, heart muscle mass change paralleled changes in heart chamber volumes.
Peptide
Tirzepatide
Outcome
Not applicableCorrelation of LV mass change with LV and left atrial volume changes
Study
n = 50
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg weekly, increasing to a maximum of 15 mg weekly · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
The LV mass change also correlated with changes in LV end-diastolic volume and left atrial end-diastolic and end-systolic volumes (P < 0.03 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging.
Summary · context
A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks.
Report a problemFND-3956686905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase not statedNCT07567378

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

JULIO GRANADOS MONTIELn = 30est. May 2026 to est. May 2029

Psoriatic Arthritis · Osteoarthitis · Knee · Diabetes (DM) · Type 2 Diabetes Mellitus (T2DM) · Obesity (Disorder) · Insulin Resistance Syndrome · Metabolic Syndrome · Heart Failure · Preserved Ejection Fraction · Coronary Artery Disease · Atrial Fibrillation (AF) · Non Alcholic Fatty Liver Disease · Sarcopenia · Pericardium

Trial page ClinicalTrials.govUpdated 12 May 2026

CompletedPhase 3Results postedNCT04847557

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Eli Lilly and Companyn = 73120 Apr 2021 to 2 Jul 2024

Obesity · Heart Failure With Preserved Ejection Fraction (HFpEF)

Trial page ClinicalTrials.govUpdated 20 Aug 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.